Elaine Wang

Agenus has Announced Five Presentations at 2025 American Society of Clinical Oncology (ASCO) GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers Agenus will present five studies at the 2025 ASCO GI Symposium, highlighting the activity of botensilimab (BOT) and balstilimab (BAL) in colorectal and gastric cancers. The data include efficacy in MSS colorectal cancer and new approaches for refractory gastric cancer. https://lnkd.in/dYShjsvz Garo Armen Marwan Fakih Filippo Ghelardi Filippo Pietrantonio Yelena Janjigian Steven Maron Dorna Jafari Pashtoon Kasi Chongkai Wang #Cancer #CancerResearch #ColorectalCancer #GastricCancer #ASCOGI2025 #ImmunoOncology #CancerTreatment #Immunotherapy #Medicine #Health #Oncology #OncoDaily

30

GHC65: #H5N1 update; #vitaminD enhances immunity; #genetherapy for #hemophilia B; #monoclonal protects against #malaria; #cryptococcus review; #vaccine #confidence in 23 #countries: see all here:

11

Four hematologic oncology researchers at Dana-Farber have been selected for the American Society of Hematology (ASH) 2024 Scholar Award: Nicoletta Cieri, MD, PhD; Reid Merryman, MD; Erin Parry, MD, PhD; and Zuzana Tothova, MD, PhD. The prestigious ASH Scholar Award provides financial support to fellows and junior faculty as they finish training and become independent researchers.  ”I’m honored to receive this prestigious award,” expresses Cieri, a postdoctoral research fellow in the Catherine Wu, MD, lab. ”My project will focus on establishing a new T-cell-based immune-gene therapy approach for acute myeloid leukemia (AML). In AML, there are few effective immunotherapy targets and, unfortunately, the chances of relapsing after transplant are relatively high. This approach will potentially enable personalized targeting of leukemia-specific targets as a therapy to confront the challenge of disease relapse after stem cell transplantation.” The award, for Merryman, will help him and his team continue research into a bispecific antibody called glofitamab, a chemotherapy-free treatment for follicular lymphoma, a slow-progressing blood cancer. ”Glofitamab activates the immune system to target and kill follicular lymphoma cells,” explains Merryman, an attending physician in the Division of Lymphoma and an assistant professor of medicine at Harvard Medical School (HMS). ”In this clinical trial, we’re hoping to create a new treatment option that does not require chemotherapy. We’re also looking to better understand predictors of response and side effects of this treatment. This award will allow me to continue this important research, which I hope will lead to better treatment options for patients.” Parry will use the award to support her lab’s research into changes in the immune system when follicular lymphoma transforms into a more aggressive lymphoma. ”We seek to define these immune system changes that occur with the transformation,” shares Parry, an attending physician in the Division of Lymphoma and the Center for Chronic Lymphocytic Leukemia, and an instructor of Medicine at HMS. ”Our hope is that our research will lead to the ability to identify patients at risk for transformation and identify potential novel strategies to harness the immune system to treat transformation.” This year, Tuthova, who earned the ASH Scholar Award as a fellow in 2017, received it for the second time. “Receiving this award again is incredibly meaningful and humbling,” expresses Tothova, an investigator in Hematologic Neoplasia at Dana-Farber and an assistant professor of medicine at HMS. The award will support Tothova’s project, which aims to identify ways to prevent RUNX1-mutant familial platelet disorder (RUNX1-FPD) from progressing to myelodysplastic syndrome (MDS) or AML. RUNX1-FPD is an inherited condition in which people with genetic mutations in the RUNX1 gene have a 50% higher lifetime risk of developing MDS or AML.

65

1 Comment

#CGOncology announces #Bond-003 topline results. 🚨 New data from the BOND-003 trial: 74.5% of high-risk BCG-unresponsive #NMIBC patients achieved a complete response with cretostimogene monotherapy! Median response duration >27 months, with favorable safety/tolerability. A potential breakthrough for bladder-sparing therapy! 🧬💊 #ReadNow details on UroToday > bit.ly/4gfq05D #PressRelease #SUO24

3

Catch up on our virtual symposium. Paolo Ghia, Università Vita-Salute San Raffaele, Milano, IT, discussed clinical developments in BTK inhibitors to treat first-line #CLL.  Watch to learn about the current and future perspectives of BTK inhibitors in CLL 👉 https://loom.ly/PisoPD0 #lymphoma #lymsm

2

🔬 New Research Highlight: Amivantamab With TKIs for Advanced NSCLC 🔬 Exciting advancements in lung cancer treatment are on the horizon! Researchers are now exploring the combination of Amivantamab with Tyrosine Kinase Inhibitors (TKIs) for advanced NSCLC patients with ALK, ROS1, or RET alterations for those progressing on current their targeted therapy. 💡 Why is this important? This combination therapy has the potential to enhance treatment outcomes for patients with specific genetic drivers of lung cancer, offering new hope for improved survival and quality of life. 📖 Dive into the details: https://lnkd.in/gEVStAau #ALKPositive #LungCancerAwareness #NSCLC

13

3 Comments

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial Ben Solomon Fabrice Barlesi Alice Shaw Walter Bordogna Roche American Society of Clinical Oncology (ASCO) https://lnkd.in/dQApcgWi #Cancer #Alectinib #ALINATrial #NSCLC #ClinicalTrial #DrugApproval #FDAApproved #JournalOfClinicalOncology #LungCancer #OncoDaily #Oncology

23

BeiGene: Charting New Frontiers of Affordable Cancer Cell Therapy with iPSC Derived Allogeneic CAR T BeiGene is focusing on rapidly progressing iPSC-derived cell therapy to create more effective and accessible treatments. Their strategy centers on developing homogeneous effector cell therapeutics that arise from a single, well-characterized GMP-grade iPSC clone that harbors multiple gene edits to enhance potency and longevity. Along with their proprietary differentiation and expansion methodologies, BeiGene attempts to overcome the insufficiencies of the traditional autologous and donor-based cell therapies. Watch more at  👉🏻  https://lnkd.in/gBh4aaGm #BeiGene #CellTherapy #iPSC #GeneEditing #BiotechInnovation #EffectorCells #GMP #CellTherapeutics #Biopharma #RegenerativeMedicine #HealthcareInnovation #Biotechnology #Therapeutics #PrecisionMedicine

80

MYC IHC could be crucial in tailoring immunotherapy approaches in NSCLC - Aakash Desai, MD, MPH ESMO - European Society for Medical Oncology Yash Ashara, MD Ying-Chun Lo https://lnkd.in/e_hr7nRp #Cancer #Oncology #LungCancer #OncoDaily #Oncology #lcsm

21

We look forward to hearing Christine Rothe, CDO of iOmx, speak at the 6th Annual Macrophage-Directed Therapies Summit in Boston on October 2nd. Christine will provide key insights into IOMX-0675, our highly differentiated, fully human, cross-specific antibody targeting LILRB1 and LILRB2. In the presentation, Christine will discuss how IOMX-0675 effectively repolarizes the tumor microenvironment, resulting in potent tumor cell killing both 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰. Also, Christine will highlight IOMX-0675's unique binding profile, which selectively antagonizes the immunosuppressive receptors LILRB1 and LILRB2 while sparing the immuno-activating family members. This differentiation results in superior macrophage repolarization and immune cell activation compared to other antibodies. 🔬   📢 Stay tuned for further updates!   Hanson Wade Group #CancerResearch #Macrophages #immunotherapy #ImmunoOncology

73

Excited to share a new publication in the Journal of Molecular Therapy which highlights the eShunt®️ Platform as a CNS gene therapy delivery method. Thanks to the teams at UMass Chan Medical School and Tufts Medical Center for your work on this study. "We're very excited about these promising preclinical results, which suggest that the eShunt System delivery approach could provide biopharmaceutical and biotechnology organizations with a minimally invasive method for delivering gene therapies directly to the cortex and brain." #bbb #CNS #drugdelivery #neurovascular #endovascular https://lnkd.in/eeKCGPm7

102

2 Comments

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

Our Labcorp Oncology medical affairs team recently published a study on Folate Receptor Alpha (FRα) expression in #ovariancancer and real-world testing patterns. 🔑 Key Findings: 💡36.3% of tested cases showed high FRα expression, predominantly in high-grade serous ovarian carcinoma. 💡Tumors from primary ovarian and adnexal sites had significantly higher FRα positivity (44.4%) compared to metastatic sites (32.5%, p = 0.02). 💡Variability in FRα expression across specimens highlights the importance of standardized testing protocols to ensure consistent and accurate biomarker evaluation. 🧬 This research underscores the critical need for understanding FRα heterogeneity to optimize therapeutic outcomes and improve care for patients with platinum-resistant ovarian cancer. 📖 Read the full study here: https://lnkd.in/eYxt-K3t ⭐️Congrats to our co-authors! Kyle Strickland Zachary Wallen Heidi Ko, DO Michelle Green Maureen Cooper Elizabeth Lyon, Mike Biorn Jennifer Armetta Rennie Q. Catie Watson, Kari Ring, Jonathan Klein Brian Caveney Eric Severson Shakti Ramkissoon

51

Elevate your Clinical Research journey by joining ACRPM as a FREE member. Unlock exclusive resources and connect with industry leaders. 🔗 #ACRPM #Networking #ClinicalResearch

1

DYK Shasqi's CAPAC technology can be used to localize RLTs ⚡ to the tumor? A major pain point for mAb-based radioconjugates is the prolonged exposure and low tumor-to-blood ratio, which causes dose-limiting toxicities. To overcome this, Shasqi separates the radionuclide from the targeting component and reunites the two at the tumor using click chemistry. This enables optimal clearance of the RLT and reduces non-specific toxicities. Shasqi's Jesse McFarland and Tri-Hung Nguyen recently presented a poster on this apprpach at the Gordon Research Conferences, 'Exploring the Power of Radioimmunobiology Via Switching the Radionuclides, Ligands and Immunotargets' in beautiful Maine. Learn more: https://bit.ly/46lz190 #RLTs

11

Breaking barriers in ADC development: What’s next? 🔎 Antibody-drug conjugates are no longer just a concept – they’re revolutionizing cancer therapy with precision-targeted treatments. However, their success hinges on robust development strategies. Allucent explores how improved analytical methods, scalable manufacturing, and compliance with global regulatory standards are key to unlocking the full potential of ADCs. 🚀 By understanding the complex interplay of science, strategy, and regulation, biotech companies can navigate the challenges of bringing ADCs from the lab to the clinic. Dive into Allucent’s roadmap for clinical success and learn how ADCs are evolving to meet the unmet needs in oncology. 🔬 Full article below ⬇️ https://lnkd.in/dmUUXcdB #ADCtherapies #oncologyinnovation #cancerresearch #targetedtherapies #precisionmedicine #bispecificADCs #pharmabreakthroughs #drugdevelopment 

9

#LupusTherapeutics, the clinical affiliate of the Lupus Research Alliance Research Alliance, quickly connected with Dr. Brad Rovin at #ACR24 to explore the transformative role CAR T could play in advancing #lupus treatment and #lupusclinicalresearch. Watch the video to learn more.

29

#ESMOAsia24 57O - A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors. Efficacy: uORR 28.6%, DCR 83.1%; SCLC (n=33) ORR 45.5%, higher without prior topotecan (56.0%) or IO (55.6%). PRs in CRPC (n=3), NSCLC (n=3), BTC (n=1). Safety: G≥3 TEAEs: neutropenia (15.9%), anemia (7.1%), thrombocytopenia (6.3%), leukopenia (4.8%). Dose reductions: 9.5%; discontinuations: 5.6%.

17

1 Comment